APRE - Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 | Benzinga
DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced four poster presentations at the American Association of Cancer Research (AACR) Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA. The posters will cover ATRN-119, Aprea's novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase.
| Presentation Details |
| Title: |
| First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations |
| Presenter |
| Nadeem Q. Mirza, MD, MPH |
| Session Title: |
| First-in-Human Phase I Clinical Trials 2 |
| Date and Time: |
| Tuesday Apr 9, 9:00 AM - 12:30 PM PT |
| Location: |
| Poster Section 48 |
| Poster Board Number: |
| 23 |
| Abstract Presentation Number: |
| CT195 |
| Title: |
| First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors |
| Presenter |
| Nadeem Q. Mirza, MD, MPH |
| Session Title: |
| First-in-Human Phase I Clinical Trials 2 |
| Date and Time: |
| Tuesday Apr 9, 9:00 AM - 12:30 PM PT |